Advanced Search

    Technical Analysis for ZNTL - Zentalis Pharmaceuticals, Inc.

    Grade Last Price % Change Price Change
    B 26.26 -0.04% -0.01
    ZNTL closed up 2.06 percent on Friday, June 2, 2023, on 1.27 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Up Down
    Historical ZNTL trend table...
    Date Alert Name Type % Chg
    Crossed Above 20 DMA Bullish -0.04%
    Golden Cross Bullish -0.04%
    Calm After Storm Range Contraction -0.04%
    NR7 Range Contraction -0.04%
    NR7-2 Range Contraction -0.04%
    Narrow Range Bar Range Contraction -0.04%
    Fell Below 20 DMA Bearish 2.02%
    Calm After Storm Range Contraction 2.02%
    NR7 Range Contraction 2.02%
    NR7-2 Range Contraction 2.02%
    Older End-of-Day Signals for ZNTL ...

       Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

    Alert Time
    Up 1% about 4 hours ago
    20 DMA Support about 4 hours ago
    Rose Above Previous Day's High about 4 hours ago
    20 DMA Resistance about 4 hours ago
    Down 2 % about 4 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    ZNTL Chart by TradingView
    Basic chart:

    Profile

    Zentalis Pharmaceuticals LLC is a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. Its lead product candidate, ZN-c5, is an oral selective estrogen receptor degrader (SERD) for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer. The company was founded by Kevin Bunker on December 23, 2014 and is headquartered in New York, NY.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Cancer Drugs Breast Cancer Treatment Of Breast Cancer Tyrosine Kinase Receptors Epidermal Growth Factor Receptor Hormones Her2 Her2/Neu Transcription Factors Molecule Therapeutics Estrogen Antiestrogens Estrogen Receptor Metastatic Breast Cancer Receptor Positive Selective Estrogen Receptor Degraders Intracellular Receptors

    Is ZNTL a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 2 Why Shares of Zentalis Pharmaceuticals Dropped This Week
    May 30 Zentalis gives up gains from ovarian cancer candidate data; down 11%
    May 26 Wells Fargo Predicts up to 70% Rally for These 2 Stocks — Here’s Why They Have Solid Upside
    May 26 Zentalis Gears Up for Phase 3 Study of Azenosertib after Positive Phase 1b Outcomes
    May 25 Zentalis Announces Presentation of Positive Phase 1b Data Demonstrating Durable Responses and Favorable Safety Profile of Azenosertib in Combination with Chemotherapy at the 2023 ASCO Annual Meeting
    May 23 Zentalis to Host Investor Call to Provide Clinical Update with Safety, Pharmacology, and Efficacy Results for Azenosertib Monotherapy and Development Plans for Monotherapy and Chemotherapy Combinations
    May 19 Where Zentalis Pharma Stands With Analysts
    May 12 Wall Street Analysts Believe Zentalis Pharmaceuticals, Inc. (ZNTL) Could Rally 95.67%: Here's is How to Trade
    May 10 Zentalis Pharmaceuticals GAAP EPS of -$1.07
    May 10 Zentalis Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Updates
    See more ZNTL news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 32.24
    52 Week Low 15.57
    Average Volume 863,788
    200-Day Moving Average 21.97
    50-Day Moving Average 21.98
    20-Day Moving Average 26.10
    10-Day Moving Average 26.87
    Average True Range 1.78
    RSI (14) 55.56
    ADX 41.62
    +DI 27.65
    -DI 10.17
    Chandelier Exit (Long, 3 ATRs) 26.13
    Chandelier Exit (Short, 3 ATRs) 26.24
    Upper Bollinger Bands 29.92
    Lower Bollinger Band 22.29
    Percent B (%b) 0.52
    BandWidth 29.23
    MACD Line 1.31
    MACD Signal Line 1.63
    MACD Histogram -0.3223
    Fundamentals Value
    Market Cap 1.07 Billion
    Num Shares 40.6 Million
    EPS -99999.99
    Price-to-Earnings (P/E) Ratio 0.00
    Price-to-Sales 0.00
    Price-to-Book 6.06
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 27.43
    Resistance 3 (R3) 27.34 26.86 27.24
    Resistance 2 (R2) 26.86 26.57 26.91 27.17
    Resistance 1 (R1) 26.57 26.38 26.72 26.66 27.11
    Pivot Point 26.09 26.09 26.16 26.13 26.09
    Support 1 (S1) 25.79 25.79 25.94 25.88 25.43
    Support 2 (S2) 25.31 25.61 25.36 25.37
    Support 3 (S3) 25.02 25.31 25.30
    Support 4 (S4) 25.11